Algert Global LLC Makes New Investment in GoodRx Holdings, Inc. $GDRX

Key Points

• Algert Global LLC purchased 277,650 shares of GoodRx Holdings, valued at approximately $1,224,000, marking a new position in the company as of the 1st quarter.
• Several institutional investors significantly increased their stakes in GoodRx Holdings, with Jacobs Levy Equity Management growing its position by 303.3% during the fourth quarter.
• GoodRx reported earnings of $0.09 per share for the latest quarter, missing analysts' estimates, with revenue slightly down year-over-year at $203.07 million, compared to an expected $205.72 million.

Algert Global LLC purchased a new position in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 277,650 shares of the company's stock, valued at approximately $1,224,000. Algert Global LLC owned 0.07% of GoodRx at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Jacobs Levy Equity Management Inc. grew its position in GoodRx by 303.3% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,061,461 shares of the company's stock worth $4,936,000 after buying an additional 798,261 shares in the last quarter. Raymond James Financial Inc. purchased a new position in GoodRx during the fourth quarter worth about $2,500,000. Dimensional Fund Advisors LP grew its position in GoodRx by 22.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,992,311 shares of the company's stock worth $9,264,000 after buying an additional 369,553 shares in the last quarter. Two Sigma Investments LP grew its position in GoodRx by 98.1% during the fourth quarter. Two Sigma Investments LP now owns 722,374 shares of the company's stock worth $3,359,000 after buying an additional 357,674 shares in the last quarter. Finally, Two Sigma Advisers LP grew its position in GoodRx by 69.1% during the fourth quarter. Two Sigma Advisers LP now owns 754,000 shares of the company's stock worth $3,506,000 after buying an additional 308,000 shares in the last quarter. 63.77% of the stock is owned by institutional investors.

Insider Buying and Selling

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the company's stock in a transaction that occurred on Thursday, July 3rd. The stock was sold at an average price of $4.80, for a total transaction of $51,249.60. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 4.17% of the stock is owned by insiders.

GoodRx Trading Down 6.8%

GDRX traded down $0.31 during midday trading on Monday, reaching $4.25. 4,067,733 shares of the company's stock traded hands, compared to its average volume of 5,675,670. The firm has a fifty day moving average of $4.58 and a two-hundred day moving average of $4.50. The stock has a market capitalization of $1.48 billion, a price-to-earnings ratio of 42.50, a P/E/G ratio of 1.99 and a beta of 1.24. The company has a debt-to-equity ratio of 0.75, a current ratio of 4.21 and a quick ratio of 4.21. GoodRx Holdings, Inc. has a 52 week low of $3.31 and a 52 week high of $8.80.

GoodRx (NASDAQ:GDRX - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.09 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.01). The business had revenue of $203.07 million for the quarter, compared to the consensus estimate of $205.72 million. GoodRx had a net margin of 4.33% and a return on equity of 8.86%. The company's revenue for the quarter was up 1.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.08 EPS. On average, equities analysts anticipate that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on GDRX. Raymond James Financial cut GoodRx from a "strong-buy" rating to an "outperform" rating in a research report on Friday, August 8th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and issued a $6.00 price objective on shares of GoodRx in a report on Monday, August 11th. UBS Group cut their price objective on GoodRx from $6.00 to $5.25 and set a "neutral" rating for the company in a report on Tuesday, May 13th. The Goldman Sachs Group cut their price objective on GoodRx from $6.00 to $5.00 and set a "neutral" rating for the company in a report on Friday, May 9th. Finally, Wells Fargo & Company decreased their price target on shares of GoodRx from $8.00 to $7.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 29th. Five investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $5.80.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.